- Home
- FPH vs TCRX Comparison
FPH vs TCRX Comparison
Compare FPH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPH
- TCRX
- Stock Information
- Founded
- FPH 2009
- TCRX 2018
- Country
- FPH United States
- TCRX United States
- Employees
- FPH N/A
- TCRX N/A
- Industry
- FPH Real Estate
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- FPH Finance
- TCRX Health Care
- Exchange
- FPH Nasdaq
- TCRX Nasdaq
- Market Cap
- FPH 267.1M
- TCRX 257.5M
- IPO Year
- FPH 2017
- TCRX 2021
- Fundamental
- Price
- FPH $3.99
- TCRX $3.94
- Analyst Decision
- FPH
- TCRX Strong Buy
- Analyst Count
- FPH 0
- TCRX 5
- Target Price
- FPH N/A
- TCRX $11.40
- AVG Volume (30 Days)
- FPH 222.3K
- TCRX 263.4K
- Earning Date
- FPH 10-17-2024
- TCRX 11-12-2024
- Dividend Yield
- FPH N/A
- TCRX N/A
- EPS Growth
- FPH 35.57
- TCRX N/A
- EPS
- FPH 0.70
- TCRX N/A
- Revenue
- FPH $196,899,000.00
- TCRX $9,362,000.00
- Revenue This Year
- FPH N/A
- TCRX N/A
- Revenue Next Year
- FPH N/A
- TCRX $3.10
- P/E Ratio
- FPH $5.55
- TCRX N/A
- Revenue Growth
- FPH 79.04
- TCRX N/A
- 52 Week Low
- FPH $2.38
- TCRX $3.93
- 52 Week High
- FPH $4.39
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- FPH 53.42
- TCRX 28.71
- Support Level
- FPH $3.64
- TCRX $5.03
- Resistance Level
- FPH $4.00
- TCRX $6.23
- Average True Range (ATR)
- FPH 0.13
- TCRX 0.41
- MACD
- FPH -0.00
- TCRX -0.15
- Stochastic Oscillator
- FPH 59.79
- TCRX 0.76
About FPH Five Point Holdings LLC
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Commercial. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.